- Home
- Publications
- Publication Search
- Publication Details
Title
Nanocell targeting using engineered bispecific antibodies
Authors
Keywords
-
Journal
mAbs
Volume 7, Issue 1, Pages 53-65
Publisher
Informa UK Limited
Online
2014-12-19
DOI
10.4161/19420862.2014.985952
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An EGFR targeting nanoparticle self assembled from a thermoresponsive polymer
- (2014) Stephen Goodall et al. JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY
- Drug delivery vehicles on a nano-engineering perspective
- (2014) Betiana Felice et al. Materials Science & Engineering C-Materials for Biological Applications
- Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
- (2013) Nicolas Bertrand et al. ADVANCED DRUG DELIVERY REVIEWS
- Injectable nanomaterials for drug delivery: Carriers, targeting moieties, and therapeutics
- (2013) David M. Webster et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Antibodies to watch in 2013
- (2013) Janice M Reichert mAbs
- Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody
- (2013) Lei Wang et al. PLoS One
- Targeted Liposome-Loaded Microbubbles for Cell-Specific Ultrasound-Triggered Drug Delivery
- (2013) Bart Geers et al. Small
- Toward aggregation-resistant antibodies by design
- (2013) Christine C. Lee et al. TRENDS IN BIOTECHNOLOGY
- A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications
- (2013) Hannah Byrne et al. TRENDS IN BIOTECHNOLOGY
- The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting
- (2013) Djordje Atanackovic et al. Human Vaccines & Immunotherapeutics
- Nanoparticles in drug delivery: Past, present and future
- (2012) P. Couvreur ADVANCED DRUG DELIVERY REVIEWS
- Advances in bispecific biotherapeutics for the treatment of cancer
- (2012) Chad May et al. BIOCHEMICAL PHARMACOLOGY
- The future of antibodies as cancer drugs
- (2012) Janice M. Reichert et al. DRUG DISCOVERY TODAY
- A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics
- (2012) Stephanie D. Steichen et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- RECRUIT-TandAbs®: harnessing the immune system to kill cancer cells
- (2012) Fionnuala McAleese et al. Future Oncology
- A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens
- (2012) Gregory L. Moore et al. mAbs
- Dual targeting strategies with bispecific antibodies
- (2012) Roland Kontermann mAbs
- Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing
- (2012) S. Metz et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions
- (2012) J. M. Perchiacca et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Panitumumab (Vectibix): Fig 1.
- (2011) J.J. Gemmete et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains
- (2011) Jürgen Schanzer et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mammalian cell protein expression for biopharmaceutical production
- (2011) Jianwei Zhu BIOTECHNOLOGY ADVANCES
- Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
- (2011) P. A. Moore et al. BLOOD
- Minicells: Versatile vectors for targeted drug or si/shRNA cancer therapy
- (2011) Jennifer A MacDiarmid et al. CURRENT OPINION IN BIOTECHNOLOGY
- Recent advances in the application of antibodies as therapeutics
- (2011) Roberta E Burden et al. Future Medicinal Chemistry
- Antibody-targeted nanoparticles for cancer therapy
- (2011) Francois Fay et al. Immunotherapy
- Therapeutic antibodies: Market considerations, disease targets and bioprocessing
- (2011) John G. Elvin et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Efficient mAb production in CHO cells incorporating PEI-mediated transfection, mild hypothermia and the co-expression of XBP-1
- (2011) Joe Codamo et al. JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY
- Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
- (2011) Twan Lammers et al. JOURNAL OF CONTROLLED RELEASE
- Targeted Drug Delivery Using Immunoconjugates
- (2011) Maria Valentina Pasquetto et al. JOURNAL OF IMMUNOTHERAPY
- Bio-inspired, bioengineered and biomimetic drug delivery carriers
- (2011) Jin-Wook Yoo et al. NATURE REVIEWS DRUG DISCOVERY
- A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies
- (2010) Martina L. Jones et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
- (2010) Syd Johnson et al. JOURNAL OF MOLECULAR BIOLOGY
- Bispecific antibodies for cancer therapy
- (2010) Patrick Chames et al. mAbs
- Structural and functional characterization of the trifunctional antibody catumaxomab
- (2010) Dirk Chelius et al. mAbs
- A dual-targeting PDGFRβ/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo
- (2010) Robert Mabry et al. mAbs
- Catumaxomab
- (2010) Rolf Linke et al. mAbs
- T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
- (2010) Ralf Lutterbuese et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties
- (2010) G. Wozniak-Knopp et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Stability engineering of scFvs for the development of bispecific and multivalent antibodies
- (2010) Brian R. Miller et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Remodeling domain interfaces to enhance heterodimer formation
- (2010) Zhenping Zhu et al. PROTEIN SCIENCE
- Next generation immunotherapeutics—honing the magic bullet
- (2009) Carrie Enever et al. CURRENT OPINION IN BIOTECHNOLOGY
- A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activityin vivo
- (2009) Timothy E. Adams et al. GROWTH FACTORS
- An Unfolded CH1 Domain Controls the Assembly and Secretion of IgG Antibodies
- (2009) Matthias J. Feige et al. MOLECULAR CELL
- Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug
- (2009) Jennifer A MacDiarmid et al. NATURE BIOTECHNOLOGY
- Engineering of stable bispecific antibodies targeting IL-17A and IL-23
- (2009) Robert Mabry et al. PROTEIN ENGINEERING DESIGN & SELECTION
- When binding is enough: nonactivating antibody formats
- (2008) Aran F Labrijn et al. CURRENT OPINION IN IMMUNOLOGY
- Molecular engineering and design of therapeutic antibodies
- (2008) Leonard G Presta CURRENT OPINION IN IMMUNOLOGY
- Single Chain Epidermal Growth Factor Receptor Antibody Conjugated Nanoparticles for in vivo Tumor Targeting and Imaging
- (2008) Lily Yang et al. Small
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started